Forest/Cypress Fibromyalgia Treatment Milnacipran Aims To Take On Pfizer’s Lyrica With More Robust Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Cypress Chief Business Officer tells the DAILY that use of a more stringent composite endpoint could provide advantage for milnacipran over Lyrica and other potential treatments.
You may also be interested in...
Milnacipran Standard Review Sets Up Launch After Cymbalta In Fibromyalgia
Cypress Biosciences tells the DAILY it is optimistic about potential differentiation for fibromyalgia candidate, even if milnacipran will be the third drug to market for the condition.
Milnacipran Standard Review Sets Up Launch After Cymbalta In Fibromyalgia
Cypress Biosciences tells the DAILY it is optimistic about potential differentiation for fibromyalgia candidate, even if milnacipran will be the third drug to market for the condition.
Forest Hopeful No More Trials Needed For Milnacipran Fibromyalgia Filing
Priority review could bring the drug to market in June, at the same time competitor Lilly’s Cymbalta may be approved for the indication.